Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study Assessing the Spatial and Kinetic Features of [18F]MK-6240 Binding in Target and Off-Target Regions to Determine the Optimal Imaging Parameters in Humans Ranging from Young Controls to Patients with Alzheimer's Disease

Trial Profile

A Study Assessing the Spatial and Kinetic Features of [18F]MK-6240 Binding in Target and Off-Target Regions to Determine the Optimal Imaging Parameters in Humans Ranging from Young Controls to Patients with Alzheimer's Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2018

At a glance

  • Drugs Fluorine-18-MK 6240 (Primary) ; Pittsburgh compound B
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Diagnostic use
  • Most Recent Events

    • 04 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top